Synthis Therapeutics
Synthis Therapeutics is developing innovative antibody drug conjugates (ADCs) that selectively inhibit TGF-ß, a cytokine involved in cancer and fibrotic diseases. Their approach aims to improve efficacy and safety over systemic TGF-ß therapies by targeting disease-driving cells with cell-selective ADCs, thereby reducing host toxicity. They focus on diseases such as cancer, fibrosis, IPF, myelofibrosis, scleroderma-ILD, Crohn’s disease, kidney fibrosis, and PAH, with the goal of providing effective targeted therapies.
Industries
Nr. of Employees
small (1-50)
Synthis Therapeutics
101 6th Avenue, 3rd Floor, JLABS-NYC, New York NY 10013
Patents
Products
Immune cell-targeted ADC for oncology indications
An antibody-drug conjugate configured to deliver an ALK5-selective kinase inhibitor payload to immune-cell targets to reduce TGF-β–mediated immunosuppression and enhance anti-tumor response; demonstrated activity in multiple tumor models in vivo.
Myofibroblast-targeted ADC for fibrotic indications
An antibody-drug conjugate configured to deliver an ALK5-selective kinase inhibitor payload to myofibroblasts to inhibit TGF-β–driven fibrosis; demonstrated efficacy in bleomycin-induced lung fibrosis models.
Linkable ALK5-selective kinase inhibitor payload
A non-cytotoxic, highly potent, linkable small-molecule kinase inhibitor selective for ALK5 designed for conjugation to antibodies and broad utility across disease areas.
Immune cell-targeted ADC for oncology indications
An antibody-drug conjugate configured to deliver an ALK5-selective kinase inhibitor payload to immune-cell targets to reduce TGF-β–mediated immunosuppression and enhance anti-tumor response; demonstrated activity in multiple tumor models in vivo.
Myofibroblast-targeted ADC for fibrotic indications
An antibody-drug conjugate configured to deliver an ALK5-selective kinase inhibitor payload to myofibroblasts to inhibit TGF-β–driven fibrosis; demonstrated efficacy in bleomycin-induced lung fibrosis models.
Linkable ALK5-selective kinase inhibitor payload
A non-cytotoxic, highly potent, linkable small-molecule kinase inhibitor selective for ALK5 designed for conjugation to antibodies and broad utility across disease areas.
Services
Collaborative development of ADC candidates including payload-linker design, antibody conjugation, and execution of animal-model efficacy and safety studies.
Business development engagement to license or co-develop targeted TGF-β ADCs and expand therapeutic indications through external partnerships.
Collaborative development of ADC candidates including payload-linker design, antibody conjugation, and execution of animal-model efficacy and safety studies.
Business development engagement to license or co-develop targeted TGF-β ADCs and expand therapeutic indications through external partnerships.
Expertise Areas
- Antibody-drug conjugate development
- Targeted TGF-β (ALK5) pathway inhibition
- Small-molecule kinase inhibitor payload design
- Antibody conjugation and linker chemistry
Key Technologies
- Antibody-drug conjugates (ADCs)
- ALK5 / TGF-β pathway inhibition
- Linkable small-molecule kinase inhibitor payloads
- Conjugation and linker chemistry for ADCs